Federica Lo Prinzi

4PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 12, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

|Jul 28, 2026
Impact of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy on pCR and Tumor Downstaging in Resectable Gastric Cancer: A Meta-Analysis.

|Jul 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.

Federica Lo Prinzi, Francesca Salani, Silvia Camera

|Oct 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.

Federica Lo Prinzi, Francesca Salani, Margherita Rimini

Pageof 1

Frequent Collaborators

2 joint publications

Gerald W Prager

2 joint publications

Giovanni Farinea

2 joint publications

Monica Niger

2 joint publications

Margherita Rimini